Investor event
On November 25, 2019, our very successful first event for investors and interested parties took place. The response of the attendees, from private persons to
On November 25, 2019, our very successful first event for investors and interested parties took place. The response of the attendees, from private persons to
With the successful proof of principle tests at the University Hospital in Tübingen, we have taken the next step towards licensing BioTempero and are thus
Prof. Dr. Hans Peter Wendel, Research Director of the Department of Thoracic, Cardiovascular and Vascular Surgery at the University Hospital in Tübingen, has been working
The management of Somapharm AG is proud and pleased about the completion and dispatch of the new share certificates for our shareholders. Since the parliamentary
The fast and precise screening method for early detection of heart disease and prevention of a surprising heart attack. Complementing ALiSE, we are launching Cardisio,
After refreshing our public appearance we are pleased to present our new website (www.somapharm.ch). Our website appears in a new design and offers extensive information
The management of Somapharm AG is very pleased to have been granted exclusive distribution rights in Europe, including Switzerland, for a new portable and miniaturized
In cooperation with the company FISO Technologies Inc. from Canada, and supported by Innoswiss, a new sensor for intensive care measurement purposes is currently being
At the beginning of May, the long-planned relocation of Somapharm AG was realized. The headquarters will remain unchanged at Ruessenstrasse 5a in Baar. Due to
Development discussions are currently taking place in the field of urodynamic flow measurements and urine volume collection in intensive care units. This should enable the
The documents for the clinical tests were submitted to the Ethics Committee of the University Hospital in Tübingen towards the end of March. The approval
Somapharm AG was able to engage one of the world’s most renowned neurosurgeons, Prof. Dr. med. Aminadav Mendelowitsch, in persona as consultant. Prof. Mendelowitsch advises